动态对比增强乳腺MRI评估新辅助化疗后残留肿瘤大小
本回顾性研究纳入2008至2011年间487例连续女性患者,在新辅助化疗后行术前动态对比增强乳腺MRI,分别于注射对比剂后90秒、360秒和590秒测量肿瘤大小,并与组织病理学全肿瘤大小及浸润性肿瘤大小对照。结果显示常规延迟期MRI与病理全肿瘤大小的一致性高于早期(ICC 0.76 vs 0.56,P < .001),常规延迟期与晚期延迟期一致性相当(ICC 0.76 vs 0.74,P = .55);小叶癌及雌激素受体阳性/人表皮生长因子受体2阴性癌在MRI上尺寸被低估。
要点
- 常规延迟期MRI(360秒)评估残留肿瘤大小与病理全肿瘤大小的一致性优于早期(90秒)(ICC 0.76 vs 0.56)。
- 小叶癌在MRI上尺寸被低估程度大于导管癌(平均差异 -2.8 cm ± 3.2 vs -0.3 cm ± 1.8,P = .004)。
- 雌激素受体阳性/人表皮生长因子受体2阴性癌在MRI上尺寸被低估程度大于人表皮生长因子受体2阳性癌和三阴性癌。
核心结论
- 延迟期MRI评估新辅助化疗后残留乳腺肿瘤大小比早期MRI更准确;小叶癌或雌激素受体阳性/人表皮生长因子受体2阴性癌在MRI上尺寸被低估。
研究设计与样本
- 回顾性研究,纳入2008至2011年间487例连续女性患者(平均年龄47.0岁±10.3,范围24-78岁),在新辅助化疗后行术前动态对比增强乳腺MRI并后续手术;以组织病理学检查(分别记录全肿瘤大小即浸润性和原位癌,以及单独浸润性肿瘤大小)为参考标准。
诊断标准与关键数值
- 常规延迟期MRI与病理全肿瘤大小的ICC为0.76,早期MRI为0.56(P < .001);常规延迟期与晚期延迟期ICC分别为0.76和0.74(P = .55);小叶癌平均大小差异为 -2.8 cm ± 3.2,导管癌为 -0.3 cm ± 1.8(P = .004);雌激素受体阳性/人表皮生长因子受体2阴性癌为 -0.8 cm ± 2.0,人表皮生长因子受体2阳性癌为 -0.3 cm ± 1.7(P = .006),三阴性癌为0.3 cm ± 1.7(P < .001)。
临床应用与阅片要点
- 阅片时应在常规延迟期(约360秒)测量残留肿瘤大小以评估新辅助化疗后残留病灶;对小叶癌及雌激素受体阳性/人表皮生长因子受体2阴性癌需注意MRI可能低估肿瘤大小。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To investigate the accuracy of dynamic contrast material-enhanced (DCE) breast MRI for determining residual tumor size after neoadjuvant chemotherapy (NAC). Materials and Methods For this retrospective study, 487 consecutive women (mean age, 47.0 years ± 10.3 [standard deviation]; range, 24-78 years) underwent preoperative DCE MRI following NAC and subsequent surgeries between 2008 and 2011. Tumor size was measured at early-phase, conventional delayed-phase, and late delayed-phase MRI (90, 360, and 590 seconds after contrast material injection, respectively). At histopathologic examination, total tumor size (both invasive and in situ) and the size of invasive tumor alone were separately recorded. Absolute agreement between tumor size at MRI and histopathologic examination was assessed by using intraclass correlation coefficient (ICC) analysis. Factors affecting size discrepancy were assessed by using multiple linear regression analysis. Results Compared with tumor size at histopathologic examination, total tumor sizes showed higher agreement at conventional delayed-phase MRI than at early-phase MRI (ICC, 0.76 vs 0.56; P ˂ .001) and comparable agreement at conventional and late delayed-phase MRI (ICC, 0.76 vs 0.74; P = .55). Lobular histologic features and tumor subtype were independently associated with greater size discrepancy (P ˂ .001). Lobular cancers were underestimated in size compared with ductal cancers (mean size discrepancy, -2.8 cm ± 3.2 vs -0.3 cm ± 1.8; P = .004). Estrogen receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative cancers were underestimated compared with HER2-positive cancers (-0.8 cm ± 2.0 vs -0.3 cm ± 1.7, P = .006) and triple-negative cancers (-0.8 cm ± 2.0 vs 0.3 cm ± 1.7, P ˂ .001). Conclusion Delayed-phase MRI is more accurate than early-phase MRI for evaluating residual breast tumor size after neoadjuvant chemotherapy. Lobular or estrogen receptor-positive/human epidermal growth factor receptor 2-negative cancers are underestimated in size at MRI compared with ductal or other subtypes. © RSNA, 2018 Online supplemental material is available for this article.
引用
- Kim SY, Cho N, Park IA, et al. Dynamic Contrast-enhanced Breast MRI for Evaluating Residual Tumor Size after Neoadjuvant Chemotherapy. Radiology. 2018. PMID: 30152744. doi:10.1148/radiol.2018172868
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。